Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–5 of 5 results
Advanced filters: Author: Bogos Agianian Clear advanced filters

  • FDA-approved RAF inhibitors poorly inhibit BRAF dimers, which limits their clinical efficacy in tumors expressing BRAFV600E mutant monomers. Here the authors identify FDA-approved Ponatinib as an effective inhibitor of BRAF monomers and dimers and designed PHI1, an inhibitor with a unique mode of action and selectivity for oncogenic BRAF dimers.

    • Xiomaris M. Cotto-Rios
    • Bogos Agianian
    • Evripidis Gavathiotis
    ResearchOpen Access
    Nature Communications
    Volume: 11, P: 1-16

  • Deregulation of BCL-2 proteins ensures resistance to apoptosis. Here, the authors describe cytosolic BAX dimers, which in cancer cells inhibit BAX activation and they develop a strategy to modulate BAX dimers to potentiate BAX-mediated apoptosis.

    • Nadege Gitego
    • Bogos Agianian
    • Evripidis Gavathiotis
    ResearchOpen Access
    Nature Communications
    Volume: 14, P: 1-20

  • Mitofusins regulate mitochondrial fusion. Here the authors identify small molecules that activate or inhibit mitofusins’ activity and modulate mitochondrial fusion and functionality. Inhibition of mitochondrial fusion promotes minority MOMP, caspase-3/7 activation, and DNA damage.

    • Emmanouil Zacharioudakis
    • Bogos Agianian
    • Evripidis Gavathiotis
    ResearchOpen Access
    Nature Communications
    Volume: 13, P: 1-20